KOSDAQElectrical Equipment058110

Mekics

₩1,358▲ 2.57%2026-11-18 close
Market Cap
₩22.1B
Turnover
₩64,628,665
Volume
50K
Shares out.
16.2M
PER
6.7×
PBR
0.5×
EPS
₩200
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit turnaround meets overseas proof stage

Mekics has posted quarterly operating profits since the fourth quarter of 2025 and is adding overseas approvals, but annual losses and the revenue decline since 2022 have not yet been reversed.

  1. 1

    Operating profit turned positive at KRW 263 million in the fourth quarter of 2025, and every quarter through the third quarter of 2026 has shown an operating profit in the filings.

  2. 2

    On an annual basis, the company has reported losses every year from 2022 to 2025, with a 2025 operating loss of KRW 2.79 billion.

  3. 3

    Revenue fell from KRW 28.8 billion in 2022 to KRW 11.3 billion in 2025, while third-quarter 2026 revenue of KRW 4.23 billion rose 51.8% from a year earlier.

  4. 4

    Consumables and other items were reported at 69.5% of sales in the first quarter of 2026, and the first US shipments, Japan consumables export and a Mexico annual supply contract were announced in the first half of 2026.

  5. 5

    Treasury shares cancelled on October 19, 2026 totaled 375,776 shares, or about KRW 3.25 billion at acquisition cost.

02

Business structure

Mekics develops and manufactures ventilators, respiratory therapy devices and patient monitors, positioning itself as a respiratory care medical device company. The core of the model is the recurring consumables sold after equipment placement.

According to a Value Finder report carried in July 2026, consumables and other items accounted for 69.5% of sales in the first quarter of 2026, followed by ventilators at 12.1%, respiratory therapy devices at 12.1% and patient monitors at 6.3%.

Consumables are replaced on a cycle, so their sales build as more equipment is installed, and the company says it is extending this lock-in model overseas.

In Korea it built references mainly among major hospitals, and a January 2026 announcement said its respiratory therapy devices were being supplied to about 70 countries.

In the United States, the HFT750U respiratory therapy device obtained FDA 510(k) clearance and is supplied to hospitals through a large local medical distributor. In Japan, equipment is supplied on an ODM basis under a local partner's brand, while consumables are supplied under Mekics' own brand.

In Mexico, the HFT750 completed COFEPRIS registration and the company signed an annual supply contract with a local partner that has a nationwide hospital consumables network.

On competition, Value Finder argues that product recalls by major manufacturers in 2021 and continuing quality problems at some products raised demand for stable new suppliers.

The company is classified under electrical equipment, but its business is respiratory care medical devices, so its product structure and regulatory framework differ substantially from those of listed peers in the same sector.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.8B-₩300M−10.7%
2025Q4₩3.2B₩300M8.2%
2026Q1₩3.9B₩400M9.4%
2026Q2₩3.9B₩200M4.6%
2026Q3₩4.2B₩700M15.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩28.8B-₩1.8B-₩2.7B−6.2%−4.0%27.8%
2023₩13.3B-₩13.9B-₩16.1B−104.6%−32.4%37.9%
2024₩11.4B-₩9.5B-₩10.3B−83.5%−26.2%51.4%
2025₩11.3B-₩2.8B-₩2.7B−24.7%−7.4%53.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On the DART annual reports, revenue fell from KRW 28.8 billion in 2022 to KRW 13.3 billion in 2023 (down 53.9% year on year), KRW 11.4 billion in 2024 (down 14.3%) and KRW 11.3 billion in 2025 (down 0.7%), declining for three consecutive years from 2023 to 2025. 2022 was the largest revenue year in the 2022 to 2025 window and 2025 the smallest.

Operating loss widened from KRW 1.77 billion in 2022 to KRW 13.9 billion in 2023, then narrowed to KRW 9.49 billion in 2024 and KRW 2.79 billion in 2025, and the company has recorded losses for four consecutive years from 2022 to 2025.

The operating margin moved from -6.2% in 2022 to -104.6% in 2023, then improved to -83.5% in 2024 and -24.7% in 2025.

Net loss attributable to controlling shareholders was KRW 2.67 billion in 2022, KRW 16.1 billion in 2023, KRW 10.3 billion in 2024 and KRW 2.7 billion in 2025, while net loss including non-controlling interests was KRW 2.83 billion, KRW 16.3 billion, KRW 10.3 billion and KRW 2.7 billion over the same years.

The 2023 widening coincided with the sharp revenue drop to KRW 13.3 billion, and a 2024 press report pointed to the decline in volumes after the end of the COVID-19 demand surge as the main cause of weak profitability. The same report cited price and cost adjustments that narrowed the operating loss.

Quarterly results moved from an operating loss of KRW 298 million on revenue of KRW 2.78 billion in the third quarter of 2025 to an operating profit of KRW 263 million on revenue of KRW 3.23 billion in the fourth quarter, with net income attributable to controlling shareholders of KRW 336 million.

In the first quarter of 2026, revenue reached KRW 3.88 billion (up 20.1% quarter on quarter), operating profit KRW 366 million (up 39.1%) and net income attributable to controlling shareholders KRW 589 million.

The second quarter of 2026 slowed, with revenue of KRW 3.86 billion (down 0.4%) and operating profit of KRW 178 million (down 51.5%). Third-quarter 2026 revenue of KRW 4.23 billion rose 9.4% from the prior quarter and 51.8% from a year earlier, and operating profit of KRW 662 million turned from a loss a year earlier.

Net income attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totals KRW 3.17 billion.

Operating cash flow went from KRW 5.74 billion in 2022 to -KRW 3.39 billion in 2023, -KRW 3.48 billion in 2024 and -KRW 2.46 billion in 2025, with outflows continuing from 2023.

The debt ratio rose from 27.8% in 2022 to 53.5% in 2025, and at the end of 2025 total equity was KRW 36.6 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 19.6 billion.

05

Industry analysis

The ventilator and respiratory therapy market went through a normalization after the COVID-19 demand surge. The company has described the global ventilator market contracting after the pandemic, which led to a return to losses from 2022.

Value Finder argues that large-scale recalls by major manufacturers in 2021 and quality problems that continued at some products increased demand from hospitals and distributors for stable new suppliers.

The global respiratory therapy market is being reshaped by supply chain changes, which widens entry opportunities for new suppliers.

By region, Mexico was described as the second-largest medical device market in Latin America, growing at an annual rate of 10.8%, and its regulator COFEPRIS applies demanding clinical data and technical document reviews.

Japan was characterized as a market with high regulatory standards and long validation periods, so securing a supply base there serves as a reference for other markets.

On competitive position, the company points to supplies to about 70 countries, CE certification for its MV50 hybrid ventilator under the EU MDR, and ISO biocompatibility certification in the United States.

This analysis does not include a market share comparison against domestic ventilator and respiratory therapy peers, so the comparison remains qualitative. Listed companies in the electrical equipment sector mostly serve power infrastructure markets, so their demand cycles are structured differently.

06

Outlook

The confirmed near-term milestones center on expanding overseas supply.

In the United States, initial HFT750U shipments began in July 2026, and the product is being delivered to hospitals in sequence through a large local partner, while the company is reported to be pursuing an exclusive consumables supply contract there.

In Japan, PMDA approval has been obtained and the first consumables export has been completed, with equipment to be supplied in sequence in line with the local partner's launch schedule.

In Mexico, an annual supply contract covering roughly 10,000 units of consumables established the supply base, and the volume is to be delivered in sequence to hospitals nationwide through the partner's distribution network.

Through KIMES 2026, the company said it would add buyers in strategic markets such as the Middle East and Latin America. On product, it is developing a hypoxemia prediction function inside its equipment in collaboration with Seoul National University Hospital and an AI startup.

Value Finder expects that as overseas equipment supply expands, consumables sales will grow and the pace of earnings improvement will accelerate. The same report argues that diversifying customers across Japan and the United States could support consumables-led recurring revenue and medium-term profitability.

How much overseas sales contribute to reported results will become visible in numbers only with the 2026 annual report.

07

Valuation

PER
6.7×
PBR
0.5×
ROE
8.3%
EPS
₩200
BPS
₩2,472
Dividend per share
₩0

The share price sits below book value per share, with the price-to-book ratio under 1 times. Trading at a discount to net asset value is a fact about the relationship between asset value and the share price.

The price-to-earnings ratio should be read as the price relative to earnings based on net income attributable to controlling shareholders over the last four quarters. Because the run of profitable quarters is short, it is too early to say this multiple reflects the durability of annual earnings.

During the four years of losses from 2022 to 2025, earnings-based multiples carried little meaning. The dividend yield is effectively close to zero, and the cancellation of treasury shares in October 2026 reduced the number of shares outstanding, which affects how per-share measures are read.

Two questions define the valuation debate: whether profitable quarters in 2026 carry through to full-year earnings, and whether overseas equipment placements convert into higher consumables sales.

The stock sits in a range where price-to-asset and price-to-earnings send different signals, which makes interpretation harder.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Sustained quarterly profit turnaround

The continued positive quarterly operating profit after the turnaround is cited as evidence of a recovering earnings base. Third-quarter 2026 revenue of KRW 4.23 billion rose 51.8% from a year earlier, and operating profit of KRW 662 million marked a swing from a loss.

Net income attributable to controlling shareholders over the last four quarters totals KRW 3.17 billion, pointing to an earnings recovery after years of annual losses.

Recurring revenue from consumables

Consumables and other items were reported at 69.5% of sales in the first quarter of 2026. As equipment installations grow, replacement consumables sales grow with them, which is cited as a factor that can dampen earnings volatility.

Value Finder has described a recurring revenue base as stable, noting that more than half of domestic sales come from consumables.

Overseas approvals and supply start

The HFT750U respiratory therapy device obtained FDA 510(k) clearance, and initial US shipments began in July 2026. In Japan, the first consumables export followed PMDA approval, while in Mexico COFEPRIS registration came with an annual supply contract. The company announced a consumables supply base of roughly 10,000 units under the Mexico contract.

09

Bear factors

Cumulative losses and cash outflows

The company has posted operating losses for four consecutive years from 2022 to 2025, and the 2025 net loss attributable to controlling shareholders was KRW 2.7 billion. Operating cash outflows have continued since 2023, reaching -KRW 2.46 billion in 2025. The debt ratio rose from 27.8% in 2022 to 53.5% in 2025, increasing the debt load relative to equity.

The low base behind revenue recovery

Revenue fell from KRW 28.8 billion in 2022 to KRW 11.3 billion in 2025. Quarterly revenue rose through 2026, but the second quarter slipped 0.4% from the prior quarter. Whether 2026 full-year revenue exceeds the 2025 level is the next checkpoint.

Uncertain overseas payoff and governance

The exclusive US consumables contract was reported as being pursued rather than signed, and the revenue scale of the annual Mexico contract has not been disclosed. How much overseas sales feed into reported results will become clear only with the 2026 annual report. A 2024 press report criticized the CEO's compensation level during a period of losses as a governance concern.

10

Risk factors

Regulatory and quality risk

Medical devices face strict country-specific approval and quality standards, and each overseas market requires a separate review. As the 2021 recalls by major manufacturers showed, a quality problem can undermine product trust and supply contracts. Even after approval, local validation periods can delay the timing of revenue.

Funding and dilution risk

Article headlines in the company's related news list reference a KRW 990 million third-party allotment rights offering. Because the company is also cancelling treasury shares, its capital policy direction is a point to track together. Given cumulative operating losses, any further fundraising could affect the shareholder structure.

Demand and currency risk

The 2023 revenue decline stemmed from lower global ventilator demand after the COVID-19 endemic phase. The company has said its cost of sales moves with price discounts and exchange rate changes. As overseas sales grow, exposure to currency movements and local pricing policies is likely to increase.

11

What to watch next

  1. From December 2026 onward (date not disclosed)

    Whether the exclusive US consumables supply contract is signed and its scale. If signed, it would show how the overseas share of consumables revenue changes.

  2. After late 2026 (timing not set)

    The formal launch of equipment by the Japanese partner and the start of sequential delivery under the Mexico annual contract.

  3. By March 31, 2027

    Full-year 2026 revenue against the 2025 level of KRW 11.3 billion, operating results, and operating cash flow in the 2026 annual report. These show whether quarterly profits carried through to the full year.

  4. By May 15, 2027

    Whether operating profit stays positive in the first quarter of 2027 and whether the overseas sales share is disclosed in the quarterly report.

12

Overall view

Mekics has posted quarterly operating profits in each quarter since the fourth quarter of 2025 as reported in the filings. Third-quarter 2026 revenue of KRW 4.23 billion rose 51.8% from a year earlier.

However, the company recorded operating losses for four consecutive years from 2022 to 2025, operating cash outflows have continued since 2023, and the debt ratio stood at 53.5% at the end of 2025.

A consumables-based revenue mix provides a recurring base, yet quarterly results have wavered, as in the second quarter of 2026. On the overseas side, the first US shipments, the Japan consumables export and the Mexico annual contract are confirmed facts, and the key question is how far they flow into reported revenue.

The company cancelled treasury shares as a shareholder return, while press reports of a third-party rights offering mean its capital policy direction also merits attention. The next checkpoint is full-year operating results and the overseas sales share in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kdpress.co.kr
  2. businesskorea.co.kr
  3. view.asiae.co.kr
  4. view.asiae.co.kr
  5. view.asiae.co.kr
  6. leadeconomy.co.kr
  7. medinet.or.kr
  8. v.daum.net
  9. ibtomato.com
  10. news.nate.com
  11. datatooza.com
  12. topstarnews.net
  13. topstarnews.net
  14. m.news.nate.com
  15. newspim.com
  16. m.news.nate.com
  17. m.news.nate.com
  18. m.news.nate.com

Report written 2026-11-12 · Data as of 2026-11-11

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis